Akeso Printed Ivonescimab plus Ligufalimab as First-Line Therapy for PD-L1-Optimistic Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 By Investing.com

Head-to-Head Section 3 Trial In comparison with Pembrolizumab Initiated

HONG KONG, Sept. 15, 2024 /PRNewswire/ — On the 2024 European Society for Medical Oncology (ESMO) Convention, Akeso launched the Section 2 medical outcomes of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or with out ligufalimab (anti-CD47 antibody AK117) for the first-line therapy of PD-L1-positive (CPS ‰¥1) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

On the information deadline of March 19, 2024, outcomes point out that for HNSCC with a excessive want for speedy tumor discount, the ivonescimab routine has demonstrated clinically significant discount in tumor dimension. When mixed with ligufalimab, each tumor shrinkage and survival advantages demonstrated additional enchancment from ivonescimab alone. Each ivonescimab alone and the ivonescimab plus ligufalimab mixture have achieved preliminary efficacy information that surpassed beforehand disclosed PD-1 research.

• The target response price (ORR) for ivonescimab monotherapy group is 30%, whereas the ORR will increase to 60% in ivonescimab plus ligufalimab group. The illness management price (DCR) is 80% for ivonescimab monotherapy group improves to 90% with ligufalimab. As of the report time, the antitumor efficacy of the ivonescimab continues to be promising, with some sufferers displaying an enchancment from steady illness (SD) to partial response (PR). The ORR for ivonescimab monotherapy and the mix of ivonescimab plus ligufalimab was to 40% and 65%, respectively.
• The median progression-free survival (mPFS) for ivonescimab monotherapy group was 5.0 months, with the 6-month PFS price not but reached. For the mix with ligufalimab group, the mPFS was 7.1 months, with a 6-month PFS price of 71.8%.
• The security profile of the ivonescimab for first-line therapy of PD-L1-positive R/M HNSCC was manageable, with no treatment-related opposed occasions (TRAE) resulting in drug discontinuation or demise in each the ivonescimab monotherapy and the ivonescimab plus ligufalimab teams.

Though programmed cell demise protein 1 (PD-1) inhibitors mixed with chemotherapy are permitted as first-line remedies for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), some sufferers exhibit poor responses to this strategy, highlighting the necessity for brand new therapy methods. Akeso has initiated a section 3 medical research evaluating ivonescimab mixed with ligufalimab versus pembrolizumab for the first-line therapy of PD-L1 constructive R/M HNSCC. This research provides the potential to offer a brand new, extremely efficient immunotherapy possibility for these sufferers and will pave the way in which for the development of most cancers immunotherapy 2.0.